PubMed Health⌕ Search

Biomedical subjects

R E Pyke

Publications and source records attributed to R E Pyke.

12 recordsLinked to original sources
PubMed1989

Double-blind comparison of alprazolam and adinazolam for panic and phobic disorders.

Subjects primarily suffering from DSM-III panic disorders (agoraphobia with panic attacks, 13 subjects; panic disorder, one subject) were tested with two drug treatments after a baseline was established using single-blind placebo capsules three times daily for 1 week. Double-blind, 4-week crossover treatments were given with alprazolam, 0.5-6.0 mg/day, and adinazolam mesylate, 10-120 mg/day. Mean final doses in mg/day were 3.1 for alprazolam and 95.5 for adinazolam mesylate. Both were broadly effective in comparison with the baseline condition. Measures included self-rated symptoms and global impressions, physician-rated global impressions, and two forms of challenges, agoraphobic and noradrenergic. The two active drugs were highly similar in overall efficacy across the sample, but alprazolam was favored globally in six subjects, and adinazolam was favored globally in another six subjects. Only two subjects obtained maximal improvement ratings without side effects with both drugs. No diagnostic or demographic factor correlated with the differential in responses to the two active treatments. No clinically significant laboratory abnormalities occurred with either drug.

Adult↗
PubMed1988

Adinazolam mesylate and placebo in depressed outpatients: a 6-week, double-blind comparison.

In 72 outpatients with DSM-III major depressive episode, adinazolam was superior to placebo in all measurements. Significantly more adinazolam-treated subjects (N = 36) than placebo subjects (N = 36) completed the study (67% vs. 19%), were rated "much" or "very much" improved (78% vs. 19%), and had a "moderate" or "marked" therapeutic effect of the drug (67% vs. 19%). The total Hamilton Rating Scale for Depression score decreased by 50% or more in 61% of the adinazolam group and in 17% of the placebo group; 72% of the adinazolam group reported that they felt "moderately," "much," or "very much" improved compared with 17% of the placebo group. The adinazolam group reported significantly more drowsiness and lightheadedness, dizziness, or faintness; the severity of these side effects decreased with time. No significant anticholinergic effects were observed.

Adult↗
PubMed1988

Alprazolam in the treatment of panic attack patients with and without major depression.

Sixteen patients with panic attacks were treated with alprazolam at an anxiety clinic between March 1982 and April 1983. For all patients charts were reviewed for baseline data and treatment results at 1 and 6 months. Quantitated self-rating scales and the Clinical Global Impressions scale were used to assess progress. Alprazolam appeared effective for panic, agoraphobia, and depressive symptoms in 7 of 11 patients with either panic disorder or agoraphobia with panic attacks (DSM-III-defined diagnoses); side effects occurred in 4 of the 11 patients, were limited to oversedation, and resulted in no discontinuations of drug. However, alprazolam was ineffective in controlling panic, agoraphobia, and depression in 5 patients with panic attacks and secondary major depressive episode; for this group of patients, side effects were apparently paradoxical and required drug discontinuation in 3 of these 5 patients.

Adult↗
PubMed1986

Norepinephrine challenges in panic patients.

Six subjects with agoraphobia with panic attacks were pretreated with placebo and restricted use of lorazepam for 4 or 5 days. Then l-norepinephrine was infused intravenously with stepwise increases to 4 to 16 micrograms/min. All subjects developed DSM-III symptoms of a panic attack. Subjective results including idiosyncratic symptoms closely resembled the spontaneous panic attacks of these subjects. Cardiac rhythm and rate changes contradicted subjective reports of racing heart and palpitations. Tachypneic and hypertensive reactivities were benign. Both anxiety symptoms and cardiovascular changes reversed rapidly and spontaneously upon discontinuation of the infusion. To validate the possibility that norepinephrine infusion may specifically and reliably simulate spontaneous panic attacks, the authors recommend further work, particularly blinded controlled studies.

Adult↗